Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: a systematic review and meta-analysis
Background The association between sodium-glucose cotransporter 2 inhibitors (SGLT2i's)
and lower extremity amputation is unclear. Purpose To systematically review randomized …
and lower extremity amputation is unclear. Purpose To systematically review randomized …
Renal physiology of glucose handling and therapeutic implications
DZ Cherney, M Kanbay… - Nephrology Dialysis …, 2020 - academic.oup.com
The rationale for using sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with
type 2 diabetes (T2D) has evolved over the last decade. Due to the effects on glucosuria and …
type 2 diabetes (T2D) has evolved over the last decade. Due to the effects on glucosuria and …
Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using bioimpedance …
A Schork, J Saynisch, A Vosseler, BA Jaghutriz… - Cardiovascular …, 2019 - Springer
Background SGLT2-inhibitors are potent antihyperglycemic drugs for patients with type 2
diabetes and have been shown to reduce body weight. However, it is unclear which body …
diabetes and have been shown to reduce body weight. However, it is unclear which body …
The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non‐alcoholic fatty liver disease
S Phrueksotsai, K Pinyopornpanish… - Journal of …, 2021 - Wiley Online Library
Abstract Background and Aim Sodium‐glucose cotransporter 2 inhibitors have shown
excellent results in glucose control in type 2 diabetes mellitus (T2DM) patients, while also …
excellent results in glucose control in type 2 diabetes mellitus (T2DM) patients, while also …
Evaluation of out-of-pocket costs and treatment intensification with an SGLT2 inhibitor or GLP-1 RA in patients with type 2 diabetes and cardiovascular disease
Importance The latest guidelines continue to recommend sodium-glucose cotransporter 2
(SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for patients …
(SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for patients …
Heterocyclic compounds as a magic bullet for diabetes mellitus: a review
U Farwa, MA Raza - RSC advances, 2022 - pubs.rsc.org
Diabetes mellitus (DM) is a major metabolic disorder due to hyperglycemia, which is
increasing all over the world. From the last two decades, the use of synthetic agents has …
increasing all over the world. From the last two decades, the use of synthetic agents has …
Sodium–Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies
TM Caparrotta, AM Greenhalgh, K Osinski, RM Gifford… - Diabetes Therapy, 2021 - Springer
Introduction Sodium–glucose co-transporter 2 inhibitors (SGLT2is) are licensed for the
treatment of type 2 diabetes (T2D) and more recently for heart failure with or without …
treatment of type 2 diabetes (T2D) and more recently for heart failure with or without …
Key results from observational studies and real‐world evidence of sodium‐glucose cotransporter‐2 inhibitor effectiveness and safety in reducing cardio‐renal risk
T Nyström - Diabetes, Obesity and Metabolism, 2024 - Wiley Online Library
Abstract Sodium‐glucose cotransporter 2 (SGLT2) inhibitors, originally designed to manage
blood sugar levels in individuals with type 2 diabetes (T2D), have emerged as a crucial …
blood sugar levels in individuals with type 2 diabetes (T2D), have emerged as a crucial …
Flash monitor initiation is associated with improvements in HbA1c levels and DKA rates among people with type 1 diabetes in Scotland: a retrospective nationwide …
A Jeyam, FW Gibb, JA McKnight, JE O'Reilly… - Diabetologia, 2022 - Springer
Aims/hypothesis We assessed the real-world effect of flash monitor (FM) usage on HbA 1c
levels and diabetic ketoacidosis (DKA) and severe hospitalised hypoglycaemia (SHH) rates …
levels and diabetic ketoacidosis (DKA) and severe hospitalised hypoglycaemia (SHH) rates …
Integrating randomized controlled trials and non-randomized studies of interventions to assess the effect of rare events: a Bayesian re-analysis of two meta-analyses
Y Zhou, M Yao, F Mei, Y Ma, J Huan, K Zou, L Li… - BMC Medical Research …, 2024 - Springer
Background There is a growing trend to include non-randomised studies of interventions
(NRSIs) in rare events meta-analyses of randomised controlled trials (RCTs) to complement …
(NRSIs) in rare events meta-analyses of randomised controlled trials (RCTs) to complement …